Avid Bioservices Inc (CDMO)

[patientlywaiting]

"With regards to Oncologi, what makes sense is that exosome test is close enough to commercialization to generate revenue to make the $8M payments a good risk/return."

From what we know about Oncologie there is absolutely no way Oncologie has the ability to commercialize and market an Exosome Test on their own. It would take an established company, a BP to do that. If that was something that was so close to happening CDMO would have been crazy to give it away, that news alone, income from an Exosome Test, would have driven the SP way higher.

"The alternative is somehow the company has financial backing to continue development/testing."

From the PR the answer to your last line.

"To this end, we intend to continue ongoing collaborations with the current investigators who are overseeing investigator-initiated trials, as well as NCCN-sponsored studies, designed to evaluate the immune modulating potential of bavituximab.”